Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Procter & Gamble says ‘very well positioned in China to continue to win’
PremiumThe FlyProcter & Gamble says ‘very well positioned in China to continue to win’
2d ago
Procter & Gamble says No. America organic sales up 4% in Q1 vs. up 7% last year
Premium
The Fly
Procter & Gamble says No. America organic sales up 4% in Q1 vs. up 7% last year
2d ago
Morning Movers: CVS Health sinks following CEO change, weak guidance
Premium
The Fly
Morning Movers: CVS Health sinks following CEO change, weak guidance
2d ago
Procter & Gamble backs FY25 EPS view $6.91-$7.05, consensus $6.97
PremiumThe FlyProcter & Gamble backs FY25 EPS view $6.91-$7.05, consensus $6.97
2d ago
Procter & Gamble sees FY25 capital spending 4%-5% of FY25 net sales
Premium
The Fly
Procter & Gamble sees FY25 capital spending 4%-5% of FY25 net sales
2d ago
Notable companies reporting before tomorrow’s open
Premium
The Fly
Notable companies reporting before tomorrow’s open
3d ago
Procter & Gamble Maintains Dividend Streak, Re-elects Directors
PremiumCompany AnnouncementsProcter & Gamble Maintains Dividend Streak, Re-elects Directors
12d ago
Procter & Gamble price target lowered to $164 from $165 at Goldman Sachs
Premium
The Fly
Procter & Gamble price target lowered to $164 from $165 at Goldman Sachs
15d ago
Procter & Gamble exec Davis sells 4,447 common shares
Premium
The Fly
Procter & Gamble exec Davis sells 4,447 common shares
15d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
iosandroid
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagramyoutube
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.